MCK · NYQ · Healthcare
McKesson Corporation
Also onShortfallConsensus DriftCrosscheck
Implied value per share
USD 1132.10
Market price
USD 874.65
Implied upside
+29.4%
5-year forecast · Perpetuity growth terminal value · Mid-year discounting · Base case
Value Per Share
Same forecast, different terminal treatment. Percentages vs price.
Forecast Cashflows
Reporting currency (USD). Outflows negative.
| Line | FY27 | FY28 | FY29 | FY30 | FY31 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | USD 457.5bn | USD 518.7bn | USD 588.2bn | USD 666.9bn | USD 756.3bn | +13.4% |
| EBIT | USD 6.8bn | USD 7.7bn | USD 8.7bn | USD 9.9bn | USD 11.2bn | +13.4% |
| NOPAT | USD 5.5bn | USD 6.3bn | USD 7.1bn | USD 8.1bn | USD 9.1bn | +13.4% |
| Add depreciation & amortisation | USD 895.6m | USD 1.0bn | USD 1.2bn | USD 1.3bn | USD 1.5bn | +13.4% |
| Less capital expenditure | USD -4.6bn | USD -5.2bn | USD -5.9bn | USD -6.7bn | USD -7.6bn | +13.4% |
| Less increase in working capital | USD -69.4m | USD -78.7m | USD -89.2m | USD -101.2m | USD -114.7m | +13.4% |
| Free cashflow to firm | USD 1.8bn | USD 2.0bn | USD 2.3bn | USD 2.6bn | USD 2.9bn | +13.4% |
| Discount factor | 0.9638 | 0.8954 | 0.8318 | 0.7728 | 0.7179 | - |
| Present value | USD 1.7bn | USD 1.8bn | USD 1.9bn | USD 2.0bn | USD 2.1bn | +5.3% |
| Present Value Of The Forecast | USD 9.6bn | |||||
Discount Rate
Source shown per component. All overridable above.
| Risk-free rate | 5.00% | US 10-year Treasury (^TNX) |
| Equity risk premium | 5.50% | Market assumption |
| Beta | 0.536 | Reported 0.307, pulled toward 1.0 (Blume) |
| Cost of equity | 7.94% | Risk-free + beta x equity risk premium |
| Cost of debt | 5.00% | Floored at the risk-free rate (implied cost of debt was lower) |
| Market capitalisation | USD 102.0bn | 92.2% of capital |
| Total debt | USD 8.6bn | 7.8% of capital, book value as a proxy |
| Tax rate | 18.7% | Effective, capped at statutory |
| WACC | 7.64% | E/V x Re + D/V x Rd x (1 - t) |
Terminal Value
Perpetuity growth is intrinsic. The exit multiple defaults to the company's current EV/EBITDA, so it answers a different question - what the shares are worth if today's rating holds and EBITDA grows as forecast.
Perpetuity growth at 2.50%
93% of EV
- Forecast FCFF, final year
- USD 2.9bn
- Capex at depreciation, working capital in reinvestment
- USD 9.9bn
- Less reinvestment at g/ROIC (4.2% of NOPAT)
- USD -411.9m
- Capitalised
- USD 9.5bn
- ROIC (reported)
- 60.0%
- Terminal value, undiscounted
- USD 188.8bn
- Terminal value, discounted
- USD 135.6bn
- Enterprise value
- USD 145.1bn
- Less net debt
- USD 4.6bn
- Equity value
- USD 140.5bn
Exit at 14.8x EBITDA
93% of EV
- Terminal value, undiscounted
- USD 188.9bn
- Terminal value, discounted
- USD 135.6bn
- Enterprise value
- USD 145.2bn
- Less net debt
- USD 4.6bn
- Equity value
- USD 140.5bn
Spread between methods: 0%.
Sensitivity
Value per share (USD) by discount rate and long-run growth.
| Long-run growth | |||||
|---|---|---|---|---|---|
| Discount rate | 1.50% | 2.00% | 2.50% | 3.00% | 3.50% |
| 5.64% | 1530.13 | 1728.01 | 1988.70 | 2347.86 | 2874.44 |
| 6.64% | 1189.36 | 1308.32 | 1455.89 | 1643.83 | 1891.43 |
| 7.64% | 961.07 | 1039.04 | 1132.09 | 1245.08 | 1385.23 |
| 8.64% | 797.94 | 852.16 | 915.14 | 989.19 | 1077.56 |
| 9.64% | 675.90 | 715.27 | 760.08 | 811.57 | 871.38 |
Outlined: this model. Green text: above today's price of 874.65. Shading: distance from this model's own value.
Priced In
What each input would have to be to justify the current price, one at a time.
| Input | Model | Implied | Gap |
|---|---|---|---|
| Revenue growth, every year | 13.4% | 7.7% | -5.7pp |
| EBIT margin | 1.5% | 1.2% | -0.3pp |
| Discount rate | 7.6% | 8.9% | +1.2pp |
Live formulas, not pasted numbers - edit a driver and the workbook reprices.
Yahoo Finance and RBA data. General information, not advice. Methodology.